Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for... see more

Recent & Breaking News (NDAQ:ALNY)

Alnylam Announces Management Change and Key Promotion

Business Wire January 3, 2017

Alnylam to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2017

Reasons To Stay Bullish On Alnylam In The New Year

Benzinga.com  December 19, 2016

Alnylam Presents Initial 2017 Pipeline Goals at R&D Day with Focus on Alnylam 2020 Strategy

Business Wire December 16, 2016

Vetr Upgrades Alnylam On News Of Streamed Press Conference

Benzinga.com  December 9, 2016

Alnylam to Webcast R&D Day

Business Wire December 8, 2016

Alnylam Presents Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Business Wire December 5, 2016

Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors

Business Wire December 4, 2016

Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors

Business Wire December 3, 2016

Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

Business Wire December 3, 2016

Alnylam Is Now The Leader In The Clinical HBV RNAi Therapy Space

Benzinga.com  November 30, 2016

The Medicines Company and Alnylam Pharmaceuticals Present Positive Results from ORION-1 Phase 2 Study of Inclisiran (formerly PCSK9si)

Business Wire November 15, 2016

Alnylam Pharmaceuticals Announces Sanofi Genzyme Opt-in Decision for Co-Development and Co-Commercialization of Fitusiran in Hemophilia and Rare Bleeding Disorders

Business Wire November 14, 2016

Research Reports Initiation on Biotech Stocks -- Alnylam Pharma, Cara Therapeutics, Emergent BioSolutions, and Alder Biopharma

PR Newswire November 14, 2016

Alnylam Pharmaceuticals and The Medicines Company Announce Publication of Phase 1 Clinical Data with Inclisiran (ALN- PCSsc) in the New England Journal of Medicine

Business Wire November 13, 2016

Alnylam to Present New Clinical Results at 58th Annual Meeting of the American Society of Hematology (ASH)

Business Wire November 3, 2016

Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity

Business Wire November 2, 2016

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Business Wire October 31, 2016

Lifshitz & Miller Law Firm Announces Investigation of Alnylam Pharmaceuticals, Inc., Chesapeake Energy Corporation, Cognizant Technology Solutions Corporation, Fenix Parts, Inc., Genworth Financial, Inc., Illumina Inc., ProNAi Therapeutics, Inc., and Supr

PR Newswire October 28, 2016

Alnylam to Webcast Conference Call Discussing Third Quarter 2016 Financial Results

Business Wire October 26, 2016